NASDAQ · VKTX
Healthcare · Biotechnology
$29.28
Down-$0.92 (-3.13%)
Updated Oct 6, 2026, 7:35 PM
SID Score
4.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · VKTX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
VKTX closed at $29.28 after 20 trading sessions, down 13.06% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $30.14 | $30.18 | $28.71 | $29.28 | 6.28M |
| Oct 2, 2026 | $30.85 | $31.09 | $29.90 | $29.94 | 6.37M |
| Oct 1, 2026 | $31.92 | $32.48 | $30.43 | $30.51 | 6.83M |
| Sep 30, 2026 | $31.855 | $33.29 | $31.20 | $32.60 | 7M |
| Sep 29, 2026 | $33.11 | $33.6469 | $31.42 | $31.81 | 8.03M |
| Sep 28, 2026 | $35.00 | $35.1896 | $32.91 | $33.03 | 8.58M |
| Sep 25, 2026 | $37.80 | $39.0451 | $35.10 | $35.56 | 13.58M |
| Sep 24, 2026 | $36.025 | $37.22 | $35.11 | $36.75 | 28.71M |
| Sep 23, 2026 | $41.76 | $43.10 | $37.71 | $41.65 | 15.73M |
| Sep 22, 2026 | $37.00 | $41.7252 | $36.34 | $40.85 | 41.23M |
| Sep 21, 2026 | $29.57 | $30.70 | $28.41 | $30.11 | 5.09M |
| Sep 18, 2026 | $29.57 | $29.68 | $28.40 | $28.99 | 2.67M |
| Sep 17, 2026 | $30.24 | $30.54 | $29.26 | $29.36 | 2.09M |
| Sep 16, 2026 | $30.02 | $30.77 | $28.80 | $29.52 | 3.01M |
| Sep 15, 2026 | $31.21 | $31.25 | $29.70 | $29.95 | 2.81M |
| Sep 14, 2026 | $31.70 | $32.43 | $31.39 | $31.53 | 1.85M |
| Sep 11, 2026 | $32.26 | $33.05 | $31.70 | $31.98 | 2.21M |
| Sep 10, 2026 | $32.50 | $32.65 | $31.87 | $32.13 | 1.72M |
| Sep 9, 2026 | $33.36 | $34.60 | $32.59 | $32.70 | 2.04M |
| Sep 8, 2026 | $34.63 | $34.81 | $33.53 | $33.68 | 1.87M |
The latest Smart Investors Daily articles mentioning VKTX.
Company
Market Activity
Research & News
VKTX research
Company profile and research snapshot.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Truist Securities | Buy | — |
| Aug 11, 2026 | JP Morgan | Overweight | — |
| Jul 30, 2026 | Canaccord Genuity | Buy | — |
| May 28, 2026 | Lake Street | Buy | — |
| Apr 30, 2026 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Yahoo · Sep 10, 2026
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.
Yahoo · Sep 10, 2026
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
Yahoo · Sep 9, 2026
Viking Therapeutics, Inc. (VKTX) closed at $32.7 in the latest trading session, marking a -2.91% move from the prior day.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VKTX.
